Ajanta Pharmaceuticals balance sheet

As of Mar 2026

Total assets: ₹6,155cr+22.7% on Mar 2025
Shareholders' equity: ₹4,527cr+19.4% on Mar 2025
Total debt: ₹212cr+8,084.9% on Mar 2025
Cash and investments: ₹663cr+8.0% on Mar 2025

₹ crore except per share

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Current assets
Non-current assets					FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	1,726	1,625	1,384	1,408
	258	176	256	209
	141	137	95.1	88.6
	28.5	25.2	18.6	25.1
	8.0	9.3	9.4	11.1
	36.5	34.5	27.9	36.2
	189	186	134	97.6
	69.3	12.7	9.4	5.3
	2,419	2,172	1,907	1,845
	939	904	828	816
	560	439	330	510
	1,854	1,183	1,247	1,057
	103	175	129	330
	1.5	1.1	1.3	1.1
	1.7	2.5	34.0	17.4
	9.0	2.3	19.0	2.5
	2,529	1,803	1,761	1,918
	268	123	133	91.6
	3,735	2,830	2,722	2,825
	0.0	13.3	8.9	8.8
	6,155	5,015	4,638	4,679
Equity
	25.1	25.1	25.3	25.3
	4,502	3,765	3,542	3,363
	4,527	3,790	3,567	3,388
	4,527	3,790	3,567	3,388
Liabilities
	0.0	0.0	0.0	1.3
	41.2	35.8	24.9	26.0
	41.2	35.8	24.9	27.2
	51.2	80.3	39.5	24.2
	118	111	109	97.7
	1.7	2.0	2.3	2.7
	212	229	175	152
	212	2.6	1.5	0.2
	544	454	463	423
	505	384	308	646
	1,261	841	773	1,069
	30.4	23.4	17.8	14.0
	5.5	40.5	44.8	33.1
	119	91.1	59.7	23.2
	1,416	996	895	1,139
	0.0	0.0	0.5	0.0
	1,628	1,225	1,071	1,291
	6,155	5,015	4,638	4,679
Trade payables — MSME split
	54.2	21.6	—	—
	490	433	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AJANTPHARM₹3,459.80

Ajanta Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersALKEM IPCALAB TORNTPHARM ABBOTINDIA ANTHEM GLAXO MEDANTA GLENMARKMcap ₹43,369 Cr

View

In ₹ Crore except Per Share As of	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Non-current Assets
+ Property, Plant & Equipment	1,407.8	1,384.1	1,624.9	1,726.4	1,726.4
+ Capital Work-in-Progress	209.5	256.5	176.3	258.1	258.1
+ Other Intangibles	88.6	95.1	137.2	140.6	140.6
+ Non-current Investments	25.1	18.6	25.2	28.5	28.5
+ Other Non-current Financial Assets	11.1	9.4	9.3	8.0	8.0
Non-current Financial Assets	36.2	27.9	34.5	36.5	36.5
+ Deferred Tax Assets	97.6	134.5	186.4	188.6	188.6
+ Other Non-current Assets	5.3	9.4	12.7	69.3	69.3
Total Non-current Assets	1,845.0	1,907.5	2,171.9	2,419.4	2,419.4
Current Assets
+ Inventories	815.6	828.4	903.9	938.5	938.5
+ Current Investments	510.3	330.1	438.7	559.9	559.9
+ Trade Receivables	1,056.9	1,246.8	1,182.7	1,853.9	1,853.9
+ Cash & Cash Equivalents	329.8	129.5	175.1	103.3	103.3
+ Other Bank Balances	1.1	1.3	1.1	1.5	1.5
+ Short-term Loans	17.4	34.0	2.5	1.7	1.7
+ Other Current Financial Assets	2.5	19.0	2.3	9.0	9.0
Current Financial Assets	1,917.9	1,760.6	1,802.6	2,529.2	2,529.2
+ Other Current Assets	91.6	133.1	123.3	267.7	267.7
Total Current Assets	2,825.2	2,722.1	2,829.7	3,735.4	3,735.4
+ Assets Held for Sale	8.8	8.9	13.3	0.0	0.0
Total Assets	4,679.0	4,638.4	5,015.0	6,154.8	6,154.8
Equity
+ Equity Share Capital	25.3	25.3	25.1	25.1	25.1
+ Other Equity / Reserves	3,362.7	3,542.1	3,765.2	4,502.0	4,502.0
Equity — Owners of Parent	3,388.0	3,567.4	3,790.3	4,527.1	4,527.1
Total Equity	3,388.0	3,567.4	3,790.3	4,527.1	4,527.1
Liabilities
+ Borrowings — Non-current	1.3	0.0	0.0	0.0	0.0
+ Other Non-current Financial Liab	26.0	24.9	35.8	41.2	41.2
Non-current Financial Liabilities	27.2	24.9	35.8	41.2	41.2
+ Provisions — Non-current	24.2	39.5	80.3	51.2	51.2
+ Deferred Tax Liabilities	97.7	108.5	110.5	117.9	117.9
+ Other Non-current Liabilities	2.7	2.3	2.0	1.7	1.7
Non-current Liabilities	151.8	175.3	228.6	212.0	212.0
+ Borrowings — Current	0.2	1.5	2.6	212.0	212.0
+ Trade Payables	422.8	463.2	454.2	544.3	544.3
+ Other Current Financial Liab	646.1	308.3	384.3	504.6	504.6
Current Financial Liabilities	1,069.0	773.0	841.1	1,260.9	1,260.9
+ Provisions — Current	14.0	17.8	23.4	30.4	30.4
+ Current Tax Liabilities	33.1	44.8	40.5	5.5	5.5
+ Other Current Liabilities	23.2	59.7	91.1	119.0	119.0
Current Liabilities	1,139.3	895.3	996.1	1,415.8	1,415.8
+ Liabilities Held for Sale	0.0	0.5	0.0	0.0	0.0
Total Liabilities	1,291.0	1,071.0	1,224.7	1,627.8	1,627.8
Total Equity & Liabilities	4,679.0	4,638.4	5,015.0	6,154.8	6,154.8
Trade Payables — MSME split
+ Dues to Micro & Small — Current	—	—	21.6	54.2	54.2
+ Dues to Other Creditors — Current	—	—	432.7	490.1	490.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.